Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Either RAC exam (Devices and Drugs) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 28 September 2012 | By Louise Zornoza,
The UK's National Institutes of Health and Clinical Excellence (NICE), the country's cost containment agency, has cleared the use of Boehringer Ingelheim's alteplase (Actilyse) for the treatment of acute ischaemic stroke by the National Health Service (NHS) in final guidance issued on 26 September.
The guidance recommends starting treatment as early as possible within 4.5 hours after onset of stroke symptoms, and after intracranial haemorrhage has been excluded by appropriate imaging techniques. Alteplase is a tissue plasminogen activator, an enzyme that degrades fibrin clots and helps restore blood flow through blocked arteries.
According to Professor Carole Longson, the Director of NICE's Health Technology Evaluation Centre, "Today's guidance recommending the use of alteplase within the extended time frame for which it is now licensed has the potential to have a significant impact on the treatment of thousands of patients." According to the UK Stroke Association, every year more than 130,000 people in England and Wales suffer a stroke.
Read more:
Read all Breaking News from RegLink
Tags: Boehringer Ingelheim, Stroke, NHS, guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.